In ovarian cancer, high expression of IGF2BP3 was associated with poor survival, and women diagnosed at advanced stages with elevated IGF2BP3 was at higher risk of developing chemoresistance[38]. Here, IGF2BP3 is linked to ovarian carcinoma.